Orthocell (ASX:OCC) Cyclically Adjusted PB Ratio: (As of Sep. 20, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ASX:OCC Orthocell Ltd ASX:OCC
44 GF Score
Price A$0.69
GF Value A$0.87
Valuation Modestly Undervalued
! 2 Warning Signs
View Full Analysis

What is Orthocell Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Orthocell  (ASX:OCC) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Orthocell Cyclically Adjusted PB Ratio Related Terms


Orthocell Cyclically Adjusted PB Ratio Historical Data

* Premium members only.

The historical data trend for Orthocell's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Orthocell Cyclically Adjusted PB Ratio Chart

Orthocell Annual Data
Trend Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25 Jun26
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 6.48 5.38 17.80 9.80

Orthocell Semi-Annual Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.07 19.36 16.55 14.28 9.18

ASX:OCC vs VRTX, REGN, MRNA: Cyclically Adjusted PB Ratio Comparison

For the Biotechnology subindustry, Orthocell's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Orthocell Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Orthocell's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Orthocell's Cyclically Adjusted PB Ratio falls into.


ASX:OCC
44GF Score
Orthocell Ltd ASX:OCC
Cyclically Adjusted PB Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Orthocell Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Orthocell's Cyclically Adjusted Book per Share for the fiscal year that ended in Jun26 is calculated as:

For example, Orthocell's adjusted Book Value per Share data for the fiscal year that ended in Jun26 was:

Adj_Book=Book Value per Share/CPI of Jun26 (Change)*Current CPI (Jun26)
=0.126/136.4868*136.4868
=0.126

Current CPI (Jun26) = 136.4868.

Orthocell Annual Data

Book Value per Share CPI Adj_Book
201706 0.046 0.000
201806 0.022 0.000
201906 0.070 0.000
202006 0.113 0.000
202106 0.089 0.000
202206 0.050 0.000
202306 0.031 0.000
202406 0.022 0.000
202506 0.060 131.551 0.062
202606 0.126 136.487 0.126

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Orthocell (ASX:OCC) Overvalued in 2026?

Based on GuruFocus' analysis, Orthocell stock appears to be undervalued. The current stock price of A$0.69 is trading 20.7% below its estimated GF Value™ of A$0.87. GuruFocus considers Orthocell to be Modestly Undervalued.

Key valuation signals for ASX:OCC:

  • Cyclically Adjusted PB Ratio:
  • GF Value™: A$0.87 vs. price of A$0.69 (20.7% below fair value)
  • GF Score™: 44/100 with 2 warning signs

No single metric tells the full story. See the ASX:OCC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Orthocell Business Description

Address 90 South Street, Building 191, Murdoch University, Murdoch, Perth, WA, AUS, 6150
Orthocell Ltd is a regenerative medicine company. The company is engaged in the development and commercialization of biological medical devices, cell therapies, and related technologies to address unmet clinical needs in human health in the regenerative medicine industry. Its product includes Striate plus; Remplir, which is a collagen wrap used in peripheral nerve repair; and OrthoACI, an implant used for the treatment of articular cartilage defects in the knee and ankle. It also has various other products in its pipeline, such as Tendon Cell Therapy and Collagen Medical Device Platform.
44GF Score

Get the complete analysis for ASX:OCC

Cyclically Adjusted PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.69
Price
A$0.87
GF Value